First Trust Dow Jones Internet Index Fund (FDN)
- Previous Close
198.20 - Open
199.22 - Bid --
- Ask --
- Day's Range
196.18 - 199.94 - 52 Week Range
137.63 - 208.31 - Volume
250,299 - Avg. Volume
408,953 - Net Assets 6.42B
- NAV 198.32
- PE Ratio (TTM) 37.06
- Yield 0.00%
- YTD Daily Total Return 6.24%
- Beta (5Y Monthly) 1.25
- Expense Ratio (net) 0.52%
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the securities that comprise the index. The index is designed to measure the performance of the largest and most actively traded securities issued by U.S. companies in the Internet industry. The index is a composite of its two sub-indices, the Dow Jones Internet Commerce Index and the Dow Jones Internet Services Index. It is non-diversified.
First Trust Advisors L.P.
Fund Family
Technology
Fund Category
6.42B
Net Assets
2006-06-19
Inception Date
Performance Overview: FDN
Trailing returns as of 4/23/2024. Category is Technology.
People Also Watch
Holdings: FDN
Top 10 Holdings (53.25% of Total Assets)
Sector Weightings
Recent News: FDN
Research Reports: FDN
Analyst Report: Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.
RatingPrice TargetFTNT: What does Argus have to say about FTNT?
FORTINET INC has an Investment Rating of BUY; a target price of $71.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium.
RatingPrice TargetFTNT: Raising target price to $72.00
FORTINET INC has an Investment Rating of HOLD; a target price of $72.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium.
RatingPrice TargetFTNT: What does Argus have to say about FTNT?
FORTINET INC has an Investment Rating of HOLD; a target price of $71.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium.
RatingPrice Target